Iatreia · Published 2025-01-01 · DOI 10.17533/udea.iatreia.333
Introduction: There is no standardized method to measure the antibody response to COVID-19 vaccination. It has been proposed that quantitative evaluation of antibodies against the virus could be a good correlate of protection. Objective: To evaluate the intensity of the immune response to COVID-19 vaccination in blood donor samples using a quantitative IgG antibody test against the receptor-binding domain (RBD) of the virus. Materials and methods: A retrospective and prospective descriptive study was conducted in blood donors from a university hospital, who underwent measurement by chemiluminescence of IgG antibodies against the SARS-CoV-2 spike protein RBD. Results: A total of 401 donors were included, with a mean age of 37.7 years (SD: 11.1). The median IgG antibody level was 1431 BAU/mL (IQR: 680–3008), with the best response observed for the Moderna vaccine, followed by Pfizer. Donors with a history of COVID-19 had higher responses. Antibody levels remained above 1000 BAU/mL between 9 and 14 months after vaccination. Conclusions: Quantitative evaluation of IgG antibodies against the SARS-CoV-2 spike protein RBD is a good correlate of protection against infection and COVID-19 vaccination.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →